This paper summaries our investigations of the immunological reactivity to Chlamydiae of patients with Reiter's syndrome (RS) and other rheumatic diseases.
Subjects, methods, and results
We examined 163 patients and 80 controls by means of antichlamydial antibody titres, lymphocyte transformation tests, and, when appropriate, urethral scrapings for the detection of inclusion bodies.
In a healthy population (Table 1) there was a low reactivity towards chlamydial antigens, whether or not the subjects carried the B27 marker, and cell-mediated and humoral reactivity were present together in only 4% of the 80 controls. Likewise in 
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There is clearly room for standardisation in the study of strain-specific and shared antibodies to chlamydial agents in RS.
Our results of lymphocyte transformation in the study of antichlamydial reactivity run parallel, in a general sense, to those of antibody status, although the two reactions are not always positive in the same patient. There is no segregation between antigens of group A or group B strains.
Conclusions
The major problems of seeking evidence of chlamydial infection in RS are clearly those of specificity and sensitivity of the tests employed. The positivity of tests in healthy controls or in patients with other rheumatic disease may be the consequence of latent infections with micro-organisms of low pathogenicity or with antigens which cross-react with those of Chlamydiae. The negativity ofchlamydia tests in 30 % of patients with RS may be due to a variety of factors. Firstly, patients' variability in immune response* may give rise to deficient responses in some.14, 81, 122 Antibody responses occur only in 30-40 % of patients with acute chlamydial infections. The possibility must be also considered that other micro-organisms (for example, Shigella, Yersinia, Klebsiella) may be triggering agents in RS.
Our findings clearly distinguish positive tests for Chlamydia in RS from those in patients with other rheumatic diseases, including ankylosing spondylitis. It is of particular interest that the expression of HLA-B27 has no influence on the prevalence of these tests but that, whatever the technique employed, 30% of patients with RS are negative for all three tests. We conclude that it is appropriate to include Chlamydia among those micro-organisms which may trigger the inflammatory rheumatic disease that we know as 'Reiter's syndrome' in the susceptible host. With knowledge of the triggering micro-organism in a subset of patients it may be possible to investigate the nature of host susceptibility. General discussion PROF. A. T. MASI: Have you studied in the same way a control group of non-gonococcal urethritis patients without reactive arthritis ? PROF. AMOR: Yes, but the control group is small in a rheumatology unit where we see few patients with pure non-gonococcal urethritis and no arthritis. Quite a proportion have complement fixing antibodies and also a positive lymphocyte transformation reaction, and are therefore not specific for RS. DR. F. C. ARNETT: What kind of antigen preparation were you using, and what stimulation index do you define as positive? PROF. AMOR: We used purified antigens of two strains-a psittacosis strain, and a human trachoma strain group A (at least a strain that uses glycogen). In answer to your second question, we tried, without success, the thymidine uptake. Now we consider a stimulation positive when on a slide there are twice as many blast cells as in the control. PROF. T. BITTER: You know, of course, that there is a whole array of antigenic specificities (labelled from A to K) in chlamydia of the kind you got from Dr. Orfila? Did you analyse the antigenic type of your strains? Indeed, some of your more disappointing results might actually be due to the fact that you used only one particular antigenic specificity out of at least 10 presently available. PROF. AMOR: I hope we can be more specific in the future. PROF 
